Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Shire Preparing For All Potential Outcomes As It Awaits Lifitegrast Approval Decision

This article was originally published in The Pink Sheet Daily

Executive Summary

The specialty firm hopes for a first-cycle approval of the dry eye candidate by the action date of Oct. 25, but is conducting an additional Phase III trial in case further symptom-relief efficacy data are needed.

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register